Neoadjuvant Therapy and in Combination With Standard of Care as Adjuvant Therapy for
Stage III-IVA Resectable Locoregionally Advanced Head and Neck Squamous Cell Carcinoma
The University of Virginia Cancer Center is conducting a clinical research study for patients who are adults ages 18 and over, and have advanced head and neck squamous cell carcinoma cancer. The purpose of this study to evaluate the combination of an experimental drug (pembrolizumab) and chemotherapy (cisplatin) in patients with advanced head and neck squamous cell carcinoma cancer. The safety and effects of the experimental drug combination will be evaluated for this study.
Participation is approximately 3-12 months of drug treatment including radiotherapy and surgery, with a longer term follow-up via a clinic visit or a phone call to keep track of how you’re doing. Study specific test will be provided at no cost to you.
Additional information can be found here: https://clinicaltrials.gov/ct2/show/NCT03765918
You will receive up to $50 per visit. Reimbursement: You will not receive reimbursement for this study.